MCID: MCR004
MIFTS: 49

Macroglobulinemia

Categories: Cancer diseases, Immune diseases, Metabolic diseases

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia 12 74 15 17
Waldenstrom Macroglobulinemia 71
Primary Macroglobulinemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9080
UMLS 71 C0024419

Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstroem's macroglobulinemia and lymphoplasmacytic lymphoma. An important gene associated with Macroglobulinemia is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs rituximab and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and spleen, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 523)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 32.0 SDC1 PAX5 MYD88 HAS1 CXCR4 CD40LG
2 lymphoplasmacytic lymphoma 31.9 SDC1 PAX5 MYD88 CXCR4 CXCL12 CD40LG
3 monoclonal gammopathy of uncertain significance 31.9 SDC1 MYD88 IL6
4 cryoglobulinemia 31.2 TNFSF13B IL6 CD40LG
5 neutropenia 30.6 IL6 CXCR4 CD40LG AKT1
6 marginal zone b-cell lymphoma 30.6 SDC1 PAX5 MYD88 CD40LG BTK
7 plasmacytoma 30.5 PAX5 IL6 CXCL12 AKT1
8 anemia, autoimmune hemolytic 30.4 TNFSF13B CD52 CD40LG
9 exanthem 30.3 SYK IL6 AKT1
10 macular retinal edema 30.3 PRKCB IL6 CXCL12
11 monoclonal paraproteinemia 30.0 SDC1 PAX5
12 toxic shock syndrome 30.0 IL6 CD40LG CD40
13 leukemia, acute myeloid 30.0 SYK PAX5 IL6 CXCR4 CXCL12 BTK
14 trypanosomiasis 29.9 TNFRSF13C MYD88 IL6
15 plasma cell leukemia 29.9 SDC1 IL6 CD40
16 myelodysplastic syndrome 29.9 IL6 CXCR4 CXCL12 BTK AKT1
17 myeloma, multiple 29.8 TNFSF13B TNFRSF17 SDC1 MYD88 IL6 CXCR4
18 splenic marginal zone lymphoma 29.8 SYK SDC1 PAX5 CD40 BTK
19 b-cell lymphoma 29.8 TNFSF13B TNFRSF13C SYK PRKCB PAX5 MYD88
20 thrombocytopenia due to platelet alloimmunization 29.7 TNFSF13B TNFRSF13B SYK CD52
21 toxoplasmosis 29.7 MYD88 IL6 CD40LG CD40
22 agammaglobulinemia 29.7 TNFRSF13B SYK IL6 CXCR4 CD40LG CD40
23 burkitt lymphoma 29.7 TNFSF13B PAX5 IL6 CD40LG CD40
24 lymphoma, mucosa-associated lymphoid type 29.6 TNFSF13B TNFRSF13C SDC1 PAX5 MYD88 CD40
25 pneumocystosis 29.6 IL6 CD52 CD40LG BTK
26 primary agammaglobulinemia 29.5 TNFRSF13C TNFRSF13B SYK
27 central nervous system lymphoma 29.4 TNFSF13B PAX5 MYD88 IL6 CXCR4 CXCL12
28 diffuse large b-cell lymphoma 29.4 TNFSF13B SYK SDC1 PAX5 MYD88 IL6
29 mature b-cell neoplasm 29.3 SDC1 PAX5 IL6 CD40
30 cryptococcal meningitis 29.3 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B
31 leukemia, acute lymphoblastic 29.3 SYK PAX5 CXCR4 CXCL12 CD40 BTK
32 mantle cell lymphoma 29.1 SYK PAX5 IL6 CXCR4 CD52 CD40LG
33 thrombocytopenia 29.1 TNFSF13B TNFRSF13C TNFRSF13B SYK PAX5 IL6
34 immunoglobulin alpha deficiency 29.0 TNFSF13B TNFRSF13C TNFRSF13B CD40LG CD40
35 combined immunodeficiency 28.8 IL6 CXCR4 CXCL12 CD70 CD40LG CD40
36 autoimmune disease 28.8 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK IL6
37 lymphoma, non-hodgkin, familial 27.7 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK SDC1
38 leukemia, chronic lymphocytic 27.5 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK SDC1
39 macroglobulinemia, waldenstrom 1 11.5
40 macroglobulinemia, waldenstrom 2 11.2
41 schnitzler syndrome 11.1
42 light chain deposition disease 10.9
43 amyloidosis 10.6
44 lymphoproliferative syndrome 10.6
45 lymphoma 10.5
46 peripheral nervous system disease 10.5
47 neuropathy 10.5
48 splenomegaly 10.5
49 lymphoma, hodgkin, classic 10.4
50 polyneuropathy 10.3

Graphical network of the top 20 diseases related to Macroglobulinemia:



Diseases related to Macroglobulinemia

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.97 SDC1 SYK
2 Decreased viability GR00055-A-2 9.97 SDC1 SYK
3 Decreased viability GR00106-A-0 9.97 CD70 PAX5
4 Decreased viability GR00154-A 9.97 BTK
5 Decreased viability GR00221-A-1 9.97 AKT1 BTK PRKCB SYK
6 Decreased viability GR00221-A-2 9.97 AKT1 BTK PRKCB SYK
7 Decreased viability GR00221-A-3 9.97 AKT1 BTK SYK
8 Decreased viability GR00221-A-4 9.97 AKT1 BTK PRKCB
9 Decreased viability GR00240-S-1 9.97 CD40LG
10 Decreased viability GR00249-S 9.97 AKT1 CD52 PRKCB SDC1 SYK TNFRSF13B
11 Decreased viability GR00301-A 9.97 BTK
12 Decreased viability GR00381-A-1 9.97 CXCR4 SDC1 TNFRSF13B
13 Decreased viability GR00386-A-1 9.97 CD52 HAS1 PAX5 SYK
14 Decreased viability GR00402-S-2 9.97 CD52 CXCR4 HAS1 PRKCB SDC1 STOML2

MGI Mouse Phenotypes related to Macroglobulinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 AKT1 BTK CD40 CD40LG CD70 CXCL12
2 homeostasis/metabolism MP:0005376 10 AKT1 BTK CD40 CD40LG CXCR4 IL6
3 immune system MP:0005387 9.93 AKT1 BTK CD40 CD40LG CD70 CXCL12
4 neoplasm MP:0002006 9.23 AKT1 BTK CXCR4 IL6 MYD88 PAX5

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4 174722-31-7 10201696
2
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
3 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Antineoplastic Agents, Immunological Phase 4
12 Immunosuppressive Agents Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Hormones Phase 4
15 Gastrointestinal Agents Phase 4
16 Hormone Antagonists Phase 4
17 Immunologic Factors Phase 4
18 Dermatologic Agents Phase 4
19 Antirheumatic Agents Phase 4
20 Antineoplastic Agents, Hormonal Phase 4
21 Immunoglobulins Phase 4
22 glucocorticoids Phase 4
23 Antibodies Phase 4
24 Antiemetics Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Antimetabolites Phase 4
27 Protective Agents Phase 4
28 Methylprednisolone Acetate Phase 4
29 Folic Acid Antagonists Phase 4
30 Vitamin B Complex Phase 4
31 Neuroprotective Agents Phase 4
32 Vitamin B9 Phase 4
33 Folate Phase 4
34
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
35
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
36
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
37
Chlorambucil Approved Phase 3 305-03-3 2708
38 Antimitotic Agents Phase 3
39 Tubulin Modulators Phase 3
40
Liposomal doxorubicin Phase 3 31703
41 BB 1101 Phase 3
42 HIV Protease Inhibitors Phase 3
43
protease inhibitors Phase 3
44
belimumab Approved Phase 2 356547-88-1 5957 10451420
45
Mesna Approved, Investigational Phase 2 3375-50-6 598
46
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
47
Iodine Approved, Investigational Phase 2 7553-56-2 807
48
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
49
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
50
Adenosine Approved, Investigational Phase 2 58-61-7 60961

Interventional clinical trials:

(show top 50) (show all 299)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
2 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
3 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
4 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
5 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Recruiting NCT04042376 Phase 4 Ibrutinib
6 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
7 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
8 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
9 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
10 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
12 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
13 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
14 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
15 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
16 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 PCI-32765 (Ibrutinib)
17 Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) Not yet recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
18 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
19 A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma Unknown status NCT03335098 Phase 2 Bortezomib
20 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
21 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
22 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
23 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
24 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
25 A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma Unknown status NCT03147885 Phase 1, Phase 2 Selinexor
26 Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia Completed NCT00936611 Phase 2 LBH589
27 Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Completed NCT01416428 Phase 1, Phase 2 oprozomib
28 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
29 A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB
30 UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia Completed NCT00083707 Phase 2 Thalidomide
31 Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed NCT00422799 Phase 2 Bortezomib;Rituximab
32 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed NCT00422656 Phase 2 Perifosine
33 A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Completed NCT00250926 Phase 2 Bortezomib;Dexamethasone;Rituximab
34 Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia Completed NCT00165295 Phase 2 Sildenafil citrate (Viagra)
35 Phase II Study of Velcade in Waldenstrom's Macroglobulinemia Completed NCT00142129 Phase 2 Bortezomib (Velcade)
36 Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Completed NCT00142116 Phase 2 Thalidomide;Rituximab
37 Carfilzomib, Rituximab, and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia Completed NCT01470196 Phase 2 Dexamethasone;Carfilzomib;Rituximab
38 An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma Completed NCT00718419 Phase 2 Enzastaurin
39 Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia Completed NCT02400437 Phase 2 Ixazomib;Dexamethasone;Rituximab
40 Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse Completed NCT02371148 Phase 2 Bortezomib-Rituximab-Bendamustine
41 An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401 Completed NCT02363439 Phase 1, Phase 2 IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
42 Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia Completed NCT01614821 Phase 2 PCI-32765
43 Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Completed NCT00976248 Phase 2 RAD001
44 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Completed NCT00832234 Phase 2 Bortezomib, Dexamethasone, Rituximab
45 Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia Completed NCT00062244 Phase 1, Phase 2
46 Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00142181 Phase 2 Campath-1H
47 A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia Completed NCT00045695 Phase 2 bortezomib
48 Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia Completed NCT00004889 Phase 2
49 S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM) Completed NCT00003416 Phase 2 dexamethasone;melphalan
50 Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00020800 Phase 2 fludarabine phosphate

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Chlorambucil
Cyclophosphamide
Ibrutinib
Thalidomide

Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

40
Bone Marrow, T Cells, Spleen, Myeloid, B Cells, Skin, Kidney

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 3450)
# Title Authors PMID Year
1
Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions. 61
33444081 2021
2
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. 61
33368476 2021
3
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. 61
33054437 2021
4
Pre-analytical mysteries: A case of severe hypervitaminosis D and mild hypercalcaemia. 61
33380896 2021
5
Multimodal imaging of two cases of retinal vein occlusion secondary to Waldenstrom macroglobulinemia. 61
33535793 2021
6
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. 61
32931398 2021
7
Cryoglobulinemic glomerulonephritis with underlying occult HBV infection and Waldenström macroglobulinemia: A case report. 61
33607837 2021
8
Clinical application of genomics in Waldenström macroglobulinemia. 61
33569985 2021
9
Solitary renal mass in Waldenström macroglobulinemia. 61
33560218 2021
10
Mast cells (MC) excess in a bone marrow (BM) associated with lymphoplasmacytic cells (LPC) in a 55-Y-old patient with Waldenström's macroglobulinemia (WM). 61
33527905 2021
11
Real-world treatment patterns and outcomes in a national study of Veterans with Waldenström macroglobulinemia, 2006-2019. 61
33606890 2021
12
CXCR4 in Waldenström's Macroglobulinema: chances and challenges. 61
33273682 2021
13
What the Silent Retina Tells You: Serous Retinal Detachment in Waldenström's Macroglobulinemia. 61
33490879 2021
14
Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases. 61
33596645 2021
15
Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. 61
33563581 2021
16
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. 61
33356554 2021
17
Inducible skin-associated lymphoid tissue (iSALT) in a patient with Schnitzler syndrome who manifested wheals on recurrent localized erythema. 61
33445206 2021
18
Tractional Retinal Detachment in a Patient With Waldenström's Macroglobulinemia. 61
33542877 2021
19
Hyperviscosity Syndrome in Rheumatoid Arthritis. 61
33452169 2021
20
Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response. 61
33512437 2021
21
Management of Waldenström macroglobulinemia in 2020. 61
33275726 2020
22
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. 61
33300385 2020
23
Proximal Nerve Root Involvement in immunoglobulin M Anti-Myelin-Associated Glycoprotein Neuropathy Presenting as Cauda Equina Syndrome. 61
33214398 2020
24
Optical coherence tomography angiography characteristics in Waldenström macroglobulinemia retinopathy: A case report. 61
33344607 2020
25
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. 61
32780514 2020
26
[Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center]. 61
33445850 2020
27
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. 61
33284944 2020
28
Emerging drugs for the treatment of Waldenström macroglobulinemia. 61
32955949 2020
29
Predictors of short-term survival in Waldenström Macroglobulinemia. 61
32662697 2020
30
Zanubrutinib for the treatment of Waldenström Macroglobulinemia. 61
33297772 2020
31
Bing-Neel syndrome: A case reports. 61
33356992 2020
32
Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. 61
33303706 2020
33
The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib. 61
33428844 2020
34
Waldenström Macroglobulinemia of the orbit: A diagnostic challenge. 61
33183084 2020
35
A prognostic index predicting survival in transformed Waldenström macroglobulinemia. 61
33179472 2020
36
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. 61
33214835 2020
37
Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond. 61
33222561 2020
38
Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. 61
33217360 2020
39
Halting the FGF/FGFR axis leads to anti-tumor activity in Waldenström's Macroglobulinemia by silencing MYD88. 61
33197938 2020
40
Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report. 61
32572827 2020
41
Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow-up data from a single-center cohort of 25 patients. 61
33208192 2020
42
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. 61
32959046 2020
43
Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. 61
32723621 2020
44
[Watch out for a second train]. 61
33026348 2020
45
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. 61
32558607 2020
46
Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. 61
32616401 2020
47
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. 61
32698195 2020
48
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. 61
32731259 2020
49
A promising new therapy of oral Ixazomib without rituximab for Waldenstrom's Macroglobulinemia. 61
33121225 2020
50
Bing-Neel syndrome revealing Waldenström's macroglobulinemia: a case report. 61
33479948 2020

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
2
Show member pathways
13.82 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
3
Show member pathways
13.68 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
4
Show member pathways
13.52 TNFSF13B TNFRSF17 TNFRSF13C IL6 CXCR4 CXCL12
5
Show member pathways
13.36 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK MYD88
6
Show member pathways
13.18 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
7
Show member pathways
13.14 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
8
Show member pathways
13.05 SYK PRKCB IL6 CXCL12 BTK AKT1
9
Show member pathways
13.05 SYK PRKCB MYD88 IL6 CD40 BTK
10
Show member pathways
12.93 SYK PRKCB MYD88 IL6 CXCR4 CXCL12
11
Show member pathways
12.85 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B IL6 CXCR4
12 12.82 PRKCB IL6 CXCR4 CXCL12 AKT1
13
Show member pathways
12.82 SYK CXCR4 CXCL12 BTK AKT1
14
Show member pathways
12.82 SYK PRKCB MYD88 IL6 CD40 BTK
15
Show member pathways
12.71 TNFSF13B TNFRSF13C PRKCB MYD88 IL6 CXCL12
16
Show member pathways
12.66 PRKCB CXCR4 CD70 CD40LG CD40 AKT1
17
Show member pathways
12.62 SYK CD40LG CD40 BTK AKT1
18
Show member pathways
12.59 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B MYD88 CD70
19 12.54 TNFSF13B TNFRSF17 SYK PAX5 MYD88 CXCR4
20
Show member pathways
12.45 SYK PRKCB CD40 BTK AKT1
21
Show member pathways
12.43 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK AKT1
22
Show member pathways
12.39 IL6 CXCR4 CXCL12 AKT1
23
Show member pathways
12.39 SYK PRKCB CD40LG CD40 AKT1
24
Show member pathways
12.38 SYK PRKCB BTK AKT1
25 12.32 TNFRSF13C IL6 CD40 AKT1
26
Show member pathways
12.29 SDC1 MYD88 IL6 AKT1
27
Show member pathways
12.27 PRKCB MYD88 CD40LG CD40 AKT1
28 12.22 SYK MYD88 IL6 AKT1
29
Show member pathways
12.21 SYK MYD88 IL6 BTK AKT1
30
Show member pathways
12.16 SYK PRKCB BTK AKT1
31
Show member pathways
12.07 SYK PRKCB BTK AKT1
32 11.88 PRKCB IL6 AKT1
33 11.86 SYK PRKCB AKT1
34 11.84 TNFSF13B IL6 CXCL12
35
Show member pathways
11.81 TNFSF13B TNFRSF17 TNFRSF13B CD40LG CD40
36
Show member pathways
11.78 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B CD70 CD40LG
37 11.74 CXCR4 CXCL12 AKT1
38 11.67 PRKCB MYD88 AKT1
39 11.66 CXCR4 CXCL12 AKT1
40 11.59 SDC1 MYD88 IL6 CD40LG CD40
41 11.5 IL6 BTK AKT1
42 11.45 TNFRSF13C TNFRSF13B CD40LG CD40 BTK
43 11.39 PRKCB MYD88 IL6
44 11.38 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PAX5 IL6
45 11.3 TNFRSF13B CXCR4 CXCL12
46 11.29 TNFSF13B TNFRSF13C SYK PRKCB MYD88 CXCL12
47 11.28 CD40LG CD40 AKT1
48 11.02 TNFSF13B IL6 CXCL12 CD70 CD40LG BTK

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.06 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK STOML2
2 plasma membrane GO:0005886 9.58 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK STOML2
3 external side of plasma membrane GO:0009897 9.43 TNFRSF13C SDC1 CXCR4 CXCL12 CD40LG CD40

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 TNFSF13B TNFRSF17 PRKCB MYD88 IL6 CXCR4
2 immune response GO:0006955 9.99 TNFSF13B IL6 CXCR4 CXCL12 CD70 CD40LG
3 adaptive immune response GO:0002250 9.95 TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB BTK
4 immune system process GO:0002376 9.91 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
5 inflammatory response GO:0006954 9.87 SDC1 MYD88 IL6 CXCR4 CD40LG CD40
6 positive regulation of interleukin-6 production GO:0032755 9.83 SYK MYD88 IL6
7 positive regulation of tumor necrosis factor production GO:0032760 9.82 SYK MYD88 IL6
8 response to organic substance GO:0010033 9.82 SDC1 BTK AKT1
9 cellular response to mechanical stimulus GO:0071260 9.8 MYD88 CD40 AKT1
10 cellular calcium ion homeostasis GO:0006874 9.8 STOML2 PRKCB CXCL12 CD40
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 MYD88 IL6 AKT1
12 positive regulation of interleukin-8 production GO:0032757 9.77 SYK MYD88 IL6
13 platelet activation GO:0030168 9.77 SYK PRKCB IL6 CD40LG CD40
14 positive regulation of interleukin-12 production GO:0032735 9.74 SYK CD40LG CD40
15 positive regulation of B cell proliferation GO:0030890 9.73 TNFSF13B TNFRSF13C CD40
16 positive regulation of interleukin-10 production GO:0032733 9.72 SYK IL6 CD40LG
17 B cell activation GO:0042113 9.71 PRKCB CD40 BTK
18 T cell costimulation GO:0031295 9.71 TNFSF13B TNFRSF13C CD40LG AKT1
19 B cell proliferation GO:0042100 9.7 CD70 CD40LG CD40
20 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 9.66 CXCR4 CXCL12
21 positive regulation of B cell differentiation GO:0045579 9.65 SYK BTK
22 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.64 MYD88 AKT1
23 positive regulation of mitochondrial membrane potential GO:0010918 9.63 STOML2 AKT1
24 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 PRKCB MYD88 IL6 CD40LG CD40 BTK
25 CD40 signaling pathway GO:0023035 9.62 CD40LG CD40
26 regulation of immunoglobulin production GO:0002637 9.62 CD40LG CD40
27 response to peptidoglycan GO:0032494 9.61 MYD88 IL6
28 telencephalon cell migration GO:0022029 9.59 CXCR4 CXCL12
29 cellular response to molecule of fungal origin GO:0071226 9.58 SYK BTK
30 B cell costimulation GO:0031296 9.58 TNFSF13B TNFRSF13C
31 response to ultrasound GO:1990478 9.46 CXCR4 CXCL12
32 positive regulation of T cell proliferation GO:0042102 9.35 TNFSF13B TNFRSF13C IL6 CD70 CD40LG
33 tumor necrosis factor-mediated signaling pathway GO:0033209 9.17 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B CD70 CD40LG

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.62 TNFRSF17 TNFRSF13C TNFRSF13B CD40
2 cytokine activity GO:0005125 9.35 TNFSF13B IL6 CXCL12 CD70 CD40LG
3 tumor necrosis factor receptor binding GO:0005164 9.33 TNFSF13B CD70 CD40LG
4 Toll-like receptor binding GO:0035325 9.26 SYK MYD88
5 signaling receptor binding GO:0005102 9.1 TNFSF13B SYK STOML2 MYD88 CXCL12 CD70

Sources for Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....